| Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B100–Reactive CD4+ T-Regulatory Cells D Wolf, T Gerhardt, H Winkels, NA Michel, AB Pramod, Y Ghosheh, ... Circulation 142 (13), 1279-1293, 2020 | 159 | 2020 |
| Blockade of HVEM for prostate cancer immunotherapy in humanized mice N Aubert, S Brunel, D Olive, G Marodon Cancers 13 (12), 3009, 2021 | 31 | 2021 |
| Targeting the human T-cell inducible COStimulator molecule with a monoclonal antibody prevents graft-vs-host disease and preserves graft vs leukemia in a xenograft murine model A Burlion, S Brunel, NY Petit, D Olive, G Marodon Frontiers in Immunology 8, 756, 2017 | 24 | 2017 |
| Divergent metabolic programmes control two populations of MAIT cells that protect the lung T Riffelmacher, M Paynich Murray, C Wientjens, S Chandra, ... Nature Cell Biology 25 (6), 877-891, 2023 | 18 | 2023 |
| Extracellular vesicles released by allogeneic human cardiac stem/progenitor cells as part of their therapeutic benefit HR Hocine, S Brunel, Q Chen, J Giustiniani, MJ San Roman, YJ Ferrat, ... Stem cells translational medicine 8 (9), 911-924, 2019 | 17 | 2019 |
| Single-cell transcriptomes and T Cell receptors of vaccine-expanded Apolipoprotein B-specific T cells FS Nettersheim, Y Ghosheh, H Winkels, K Kobiyama, C Durant, ... Frontiers in Cardiovascular Medicine 9 (2022), 3656, 2023 | 4 | 2023 |
| TNFRSF14 (HVEM) is a novel immune checkpoint for cancer immunotherapy in humanized mice N Aubert, S Brunel, D Olive, G Marodon | 4 | 2019 |
| Late-rising CD4 T cells resolve mouse cytomegalovirus persistent replication in the salivary gland S Brunel, G Picarda, A Gupta, R Ghosh, B McDonald, R El Morabiti, ... PLoS Pathogens 20 (1), e1011852, 2024 | 2 | 2024 |
| TNFRSF14 (HVEM) is a novel immune checkpoint blockade that can be targeted by a monoclonal antibody to improve anti-tumor response in humanized mice S Brunel, N Aubert, D Olive, G Marodon bioRxiv, 711119, 2019 | 2 | 2019 |
| Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice. Cancers 2021, 13, 3009 N Aubert, S Brunel, D Olive, G Marodon s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| PD-1 and CD73 on naive CD4+ T cells synergistically limit responses to self FS Nettersheim, S Brunel, RS Sinkovits, SS Armstrong, P Roy, M Billitti, ... Nature Immunology, 1-11, 2024 | | 2024 |
| A noncanonical glycoprotein H complex enhances cytomegalovirus entry MJ Norris, LA Henderson, MNA Siddiquey, J Yin, K Yoo, S Brunel, ... bioRxiv, 2024 | | 2024 |
| Abstract B055: Harnessing cytomegalovirus immunity against pancreatic tumors for immunotherapy R Marrocco, J Patel, R Medari, S Sun, K Gulay, A Martsinkovskiy, S Brunel, ... Cancer Research 84 (17_Supplement_2), B055-B055, 2024 | | 2024 |
| PD-1 and CD73 synergistically limit CD4 T cell responses to autoantigens F Nettersheim, S Brunel, R Sinkovits, S Armstrong, P Roy, M Billitti, ... The Journal of Immunology 212 (1_Supplement), 1103_6106-1103_6106, 2024 | | 2024 |
| HVEM is a novel immune checkpoint for prostate cancer immunotherapy in humanized mice N Aubert, S Brunel, D Olive, G Marodon Preprints, 2021 | | 2021 |
| Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée: potentiel thérapeutique et effets immunologiques S Brunel Paris 6, 2017 | | 2017 |
| HVEM blockade initiates tumor cell death by innate immunity and improves anti-tumor response by human T cells in NSG immuno-compromised mice S Brunel, N Aubert, P KC, D Olive, G Marodon | | |